Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00381030 · ClinicalTrials.gov registry record · Phase 4

Effects of Carvedilol on Health Outcomes in Heart Failure

A Phase 4 study of Heart Failure, Congestive, sponsored by Denver Health and Hospital Authority.

Completed
Registry status
Phase 4
Development phase
100
Enrollment target
1
Study location

NCT00381030 is a Phase 4 study of Heart Failure, Congestive that has completed, run by Denver Health and Hospital Authority. The registered enrollment target is 100 participants, below the 639-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00381030, a Phase 4 study of Heart Failure, Congestive, has completed, sponsored by Denver Health and Hospital Authority.

COMPLETED
Registry status
Phase 4
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of our study was to determine if a strategy of starting a heart medication (Beta-blocker) before patients leave the hospital and then being seen by a nurse manager would reduce subsequent hospitalizations compared to usual care. Hypothesis: A nurse-directed heart failure management program with inpatient initiation of beta blockers will improve health outcomes in a vulnerable, predominantly Hispanic and African American population.

Conditions Studied

Interventions

  • DRUG carvedilol plus nurse management

Study Locations (1)

Colorado

  • Denver Health Medical Center - Denver

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2002-10
Est. Completion 2005-03
Phase Phase 4

What the Registry Record Tells You About NCT00381030

The ClinicalTrials.gov registry entry for NCT00381030 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 639-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (84% lower). The listed sponsor is Denver Health and Hospital Authority, which has 73 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 1 intervention - of which carvedilol plus nurse management is the first listed.

NCT00381030 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT00381030 about?

NCT00381030 is a clinical study titled "Effects of Carvedilol on Health Outcomes in Heart Failure". The purpose of our study was to determine if a strategy of starting a heart medication (Beta-blocker) before patients leave the hospital and then being seen by a nurse manager would reduce subsequent hospitalizations compared to usual care. Hypothesis: A nurse-directed heart failure management prog...

What is the current status of trial NCT00381030?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2002-10. Estimated completion is 2005-03.

What conditions does trial NCT00381030 study?

This clinical trial studies the following conditions: Heart Failure, Congestive.

What interventions are being tested in trial NCT00381030?

The interventions under investigation include: carvedilol plus nurse management (DRUG).

Who is sponsoring clinical trial NCT00381030?

This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00381030 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure, Congestive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.